Development of a green Komagataella phaffii cell factory for sustainable production of plant-derived sesquiterpene (–)-α-bisabolol

Gespeichert in:
Bibliographische Detailangaben
Titel: Development of a green Komagataella phaffii cell factory for sustainable production of plant-derived sesquiterpene (–)-α-bisabolol
Autoren: Jintao Cheng, Zhongji Pu, Jiali Chen, Dingfeng Chen, Baoxian Li, Zhengshun Wen, Yuanxiang Jin, Yanlai Yao, Kan Shao, Xiaosong Gu, Guiling Yang
Quelle: Synth Syst Biotechnol
Synthetic and Systems Biotechnology, Vol 10, Iss 1, Pp 120-126 (2025)
Verlagsinformationen: Elsevier BV, 2025.
Publikationsjahr: 2025
Schlagwörter: 0301 basic medicine, 0303 health sciences, 03 medical and health sciences, Microbial cell factory, QH301-705.5, (–)-α-Bisabolol, Original Research Article, Biology (General), Enzyme engineering, Metabolic engineering, TP248.13-248.65, Komagataella phaffii, Biotechnology
Beschreibung: (-)-α-Bisabolol is a plant-derived sesquiterpene derived from Eremanthus erythropappus, which can be used as a raw material in cosmetics and has anti-inflammatory function. In this study, we designed six mutation sites of the (-)-α-bisabolol synthase BOS using the plmDCA algorithm. Among these, the F324Y mutation demonstrated exceptional performance, increasing the product yield by 73 %. We constructed a de novo (-)-α-bisabolol biosynthesis pathways through systematic synthetic biology strategies, including the enzyme design of BOS, selection of different linkers in fusion expression, and optimization of the mevalonate pathway, weakening the branching metabolic flow and multi-copy strategies, the yield of (-)-α-bisabolol was significantly increased, which was nearly 35-fold higher than that of the original strain (2.03 mg/L). The engineered strain was capable of producing 69.7 mg/L in shake flasks. To the best of our knowledge, this is the first report on the biosynthesis of (-)-α-bisabolol in Komagataella phaffii, implying this is a robust cell factory for sustainable production of other terpenoids.
Publikationsart: Article
Other literature type
Sprache: English
ISSN: 2405-805X
DOI: 10.1016/j.synbio.2024.09.006
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39493337
https://doaj.org/article/52eeaf36fb78484ca76bae95c0b02874
Rights: CC BY NC ND
Dokumentencode: edsair.doi.dedup.....74543312cdb62e3333dd512974eb2b8b
Datenbank: OpenAIRE
Beschreibung
Abstract:(-)-α-Bisabolol is a plant-derived sesquiterpene derived from Eremanthus erythropappus, which can be used as a raw material in cosmetics and has anti-inflammatory function. In this study, we designed six mutation sites of the (-)-α-bisabolol synthase BOS using the plmDCA algorithm. Among these, the F324Y mutation demonstrated exceptional performance, increasing the product yield by 73 %. We constructed a de novo (-)-α-bisabolol biosynthesis pathways through systematic synthetic biology strategies, including the enzyme design of BOS, selection of different linkers in fusion expression, and optimization of the mevalonate pathway, weakening the branching metabolic flow and multi-copy strategies, the yield of (-)-α-bisabolol was significantly increased, which was nearly 35-fold higher than that of the original strain (2.03 mg/L). The engineered strain was capable of producing 69.7 mg/L in shake flasks. To the best of our knowledge, this is the first report on the biosynthesis of (-)-α-bisabolol in Komagataella phaffii, implying this is a robust cell factory for sustainable production of other terpenoids.
ISSN:2405805X
DOI:10.1016/j.synbio.2024.09.006